Better Growth Stock: Moderna vs. Teladoc
It may be a bit early to establish Moderna's (NASDAQ: MRNA) and Teladoc Health's (NYSE: TDOC) lasting growth stock status by looking at the past couple of years. Both have been through extraordinary times. Moderna launched the coronavirus vaccine as its first product in 2020 -- and vaccinated a good share of the population. Teladoc saw revenue and virtual medical visits soar in the triple digits as people opted to stick close to home.
As a result, Moderna went from zero product revenue to billions of dollars in a matter of months. And Teladoc's revenue crossed the $1 billion mark for the first time ever. Moderna's and Teladoc's situations were temporary. But that doesn't mean we shouldn't bet on them for more growth in the coming months or years. Both are on the right path. Which one is the better stock to buy now? Let's find out.
Moderna reported a whopping $18.5 billion in coronavirus vaccine revenue last year. And the company expects even more this year -- at least $21 billion, according to advance purchase agreements.
Source Fool.com
